On 21 March 2018, orphan designation (EU/3/18/1998) was granted by the European Commission to Blue-Reg Europe, France, for patidegib for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome).
The sponsorship was transferred to new Pharma Gateway AB, Sweden in April 2020.
|Disease / condition||
Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.